<DOC>
	<DOCNO>NCT00950742</DOCNO>
	<brief_summary>Study determine Maximum Tolerated dose BIBW 2992 give combination Herceptin速</brief_summary>
	<brief_title>Phase I Open Label Trial Assess Safety BIBW 2992 ( Afatinib ) Combination With Herceptin速 Patients With HER2-positive Advanced Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Female patient age &gt; 18 year . 2 . Advanced metastatic breast cancer overexpresses HER2 ( immunohistochemistry 3+ 2+ gene amplification FISH ) . Prior treatment Herceptin速 Lapatinib速 ( adjuvant metastatic setting ) permit require . Exclusion criterion : Patients untreated symptomatic brain metastasis . Prior treatment EGFR target therapy treatment EGFR HER2 inhibit drug within past four week start therapy concomitantly study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>